OncoMatch

OncoMatch/Clinical Trials/NCT06966232

Prophylactic or Preemptive Entecavir in Patients With Gastrointestinal Cancer Who Are Inactive Hepatitis B Carriers

Is NCT06966232 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies Entecavir for gastrointestinal cancers.

Phase 3RecruitingSun Yat-sen UniversityNCT06966232Data as of Jun 2026Location: China

Treatment: EntecavirThere has been no report on whether the patients with gastrointestinal cancer who are also inactive hepatitis B carriers should receive prophylactic use or preemptive use of an anti-viral drug entecavir during anti-tumor therapy. This open, multicentre, phase 3, randomized controlled clinical trial aims to compare the impact of the prophylactic use or preemptive use of an anti-viral drug entecavir on the outcomes of patients with gastrointestinal cancer who are also inactive hepatitis B carriers during chemotherapy or immunotherapy and the subsequent follow-ups, including two cohorts of chemotherapy and immunotherapy.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

Entecavir

Cancer type

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Cholangiocarcinoma

Esophageal Carcinoma

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Demographics

Ages ≤ 75

Prior therapy

Max 2 prior lines

Cannot have received: anti-HBV therapy

Received anti-HBV therapy for chronic hepatitis B within 6 months before enrollment

Lab requirements

Liver function

normal liver function tests including alanine aminotransferase (alt), aspartate aminotransferase alkaline (ast), and bilirubin

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT06966232 currently recruiting?

Yes, this trial is currently recruiting patients.

Are there prior therapy exclusions?

Yes. Prior anti-HBV therapy disqualifies patients from enrollment.

Is there an age limit?

Yes. Patients must be 75 years or younger.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify